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Syncope Outcomes in a
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Low Risk Is Not No Risk*
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Calgary, Alberta, Canada
Much of what we know about syncope—its causes, inves-
tigation, outcome, and treatment—comes from selected
populations in often quite atypical settings. These are
usually academic, tertiary care referral centers, with local
expertise and reputations in the assessment and treatment of
syncope. Often the studies are led by cardiac electrophysi-
ologists or other specialists with particular interests. One
would not be surprised if the patients were equally atypical.
Indeed, many studies focus on highly symptomatic patients
or those with obvious and quite significant underlying
comorbidities (1,2), and the walking well are often excluded.
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A recent position paper of the Canadian Cardiovascular
Society reviewed international data and concluded that the
1-month and 1-year risks of death after an emergency
department admission for syncope are 0.7% and 10%,
respectively (3). Although these studies are of considerable
interest and usefulness for physicians treating patients who
resemble those in the studies, they also provide a mild sense
of free-floating unreality: just who are the bulk of syncope
patients, and what happens to them? In particular, within an
entire health care system, what is the outcome of apparently
low-risk patients? This is of considerable importance to
health administrators and planners who need to know about
this large denominator to provide for their health care.
The paper by Ruwald et al. (4) from Denmark in this
issue of the Journal makes a significant contribution here.
The Danish health care system has nationwide databases.
This allowed Ruwald et al. (4) to study every patient in
Denmark with a first-time syncope admission to an emer-
gency department or hospital from 2001 through 2009 and
then select for further analysis the 40% of the patients who
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Libin Cardiovascular Institute of Calgary, Calgary, Alberta, Canada. Dr.
Sheldon has reported that he has no relationships relevant to the contents of this paper
to disclose.appeared to have no pre-existing comorbidity. They did this
by screening for comorbidities based on diagnostic codes
and separately by linking the health care database to the
pharmacy database and screening for antihypertensive and
hypoglycemic medications. Altogether they found 37,017
patients with no known related comorbidities at the time of
presentation and then tracked their subsequent journeys
through administrative databases for a mean of 4.5 years,
along with those of 185,085 well-matched control subjects.
Ruwald et al. compared the groups with outcomes such as
death, recurrent syncope, cardiovascular morbidity, and
cardiac device insertion.
Not surprisingly (5), the overall risk of death in this
apparently well population was very low and not different
from that of the control group. The yearly overall mortality
was 1.4% in each group over a mean 4.5-year follow-up.
This reassuringly agrees with older, much smaller studies
that concluded that syncope on the whole has a benign
prognosis (6). It also contrasts starkly with the relatively
high mortality reported in many recent studies based in
emergency departments (3,7,8), wherein the annual mortal-
ity rate averages 10% (3). These include patients with
significant comorbidities. The authors did find excess mor-
tality in patients 25 to 74 years of age (the age of 74 years
was defined as the upper limit of middle age), and their
hazard ratio was 1.2 to 2.2 that of age-matched control
subjects. This excess mortality was mirrored by a substantial
increase in the likelihood of a cardiovascular hospitalization
or insertion of a cardiac rhythm control device. Interest-
ingly, much older patients with syncope did not have an
excess risk of death compared with the control subjects.
This paper provides solid grounding of our understanding
of the numbers and long-term outcome of apparently well
syncope patients in an entire nation, and this alone is a
unique contribution. It is a comprehensive countrywide
snapshot of the outcome of apparently low-risk syncope
patients. Few other countries are able to mount such an
effort, and the authors (and administrators) should be
congratulated. It shows that even low-risk patients with
apparently no comorbidities on presentation need to be
reviewed carefully, although this is not a unique or novel
insight. The latter highlights the difficulty faced by all
physicians who assess syncope patients: how to risk-stratify
accurately (3,7,8) and how to spend health care resources
efficiently and wisely (9). We are still far from solving this
problem; syncope consumed $2.4 billion in the United
States in 2003 alone (10), about as much as asthma did.
Finally, their paper highlights the precision around small
point estimates that large administrative databases can
provide.
This report provides a strong basis for related questions,
but it also highlights a gap between administrative data at
this level and data at the level of the clinic and the patient.
The first gap is the eventual diagnosis and outcome. For
example, we know almost nothing about the diagnosis of
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graphic data. In many other studies, abnormal electrocar-
diographic findings provide significant prognostic value (3).
We can infer that many had heretofore undeclared cardio-
vascular disease because they had an increased likelihood of
subsequent cardiovascular admissions, stroke, and insertion
of pacemakers and defibrillators. We have no idea of the
cause of their deaths nor how their courses compared with
those of syncope patients with previously declared comor-
bidities. There is no information on their course in hospital
or subsequent clinics nor on their health care consumption
and the efficiency of their workup. What is missing and
would be of considerable interest is information on how
physicians made their decisions to investigate (11,12) and
with which tools. Several risk-stratification tools based in
the emergency department have appeared over the past 10
years, but they generally would have screened out this group
as they usually feature markers such as known heart disease,
heart failure, anemia, dyspnea, and advancing age (3,8).
Finally, there are the limitations based on studies from
single countries. How do these patients and this health care
system compare with those of other countries, particularly
those without anything resembling a unitary system?
Ruwald et al. provide an important contribution that will
set the context for more studies on how to provide syncope
assessment. Given the lack of declared baseline comorbidi-
ties, what are the most prevalent outcomes? Where should
clinical suspicion be directed, and how should we target
resources at the most likely undeclared diagnosis? Where
and when in the time after admission was the diagnosis
made? What are the costs of assessing this low-risk group of
patients? Given the overall low risk of the patients, these
become nontrivial considerations. What is the most effective
selection of tests and type of health care provider who could
provide early assessment in a syncope clinic? Answers to these
will emerge in the next few years and will be solidly grounded
in countrywide studies such as the one by Ruwald et al. (4). sReprint requests and correspondence: Dr. Robert Sheldon,
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